Abstract: The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising: a) a pharmaceutically acceptable solvent, b) a first compound comprising diclofenac and/or lornoxicam or a pharmaceutically acceptable salt or solvate thereof, c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, and d) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof, the pharmaceutical composition further comprising a cortisone derivative or a pharmaceutically acceptable salt or solvate thereof.
Abstract: Provided is a pharmaceutical composition including gastrodin and a use thereof for the prevention or the treatment of amyotrophic lateral sclerosis. The pharmaceutical composition is effective in reducing neuronal axon degeneration and neurofibromin accumulation, improving symptoms of amyotrophic lateral sclerosis and extending life of patients of amyotrophic lateral sclerosis.
Abstract: The invention relates to a method for separating a polynucleotide insert from a polynucleotide vector backbone. The backbone has a plurality of cleavage sites distributed such that the backbone is converted into fragments when the sites are cleaved. This allows straightforward separation of the insert from the backbone. The invention also relates to backbones for use in such a method, and to plasmids and kits comprising such backbones.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
April 16, 2024
Assignee:
ProteoNic Biotechnology IP B.V.
Inventors:
Bart Marinus Engels, Raymond Michael Dimphena Verhaert, Maurice Wilhelmus Van der Heijden
Abstract: Disclosed is a viral receptor that contains a sialic acid compound at one side thereof to provide binding affinity to a virus, and contains a lipid at the other side thereof, and that can be widely used for the treatment of viral infections based on this characteristic.
Abstract: Antioxidant composition for increasing the levels of vitamins and reducing oxidative damage in a subject; the composition comprises an active agent, containing polydatin and acetylcysteine.
Abstract: The present disclosure relates to biomarkers and methods for determining or predicting survival of patients with low grade glioma (LGG) or pediatric neuroblastoma. Further disclosed are methods of diagnosing and treating patients with low grade glioma (LGG) or pediatric neuroblastoma.
Type:
Grant
Filed:
March 17, 2022
Date of Patent:
April 9, 2024
Assignee:
University of South Florida
Inventors:
George Blanck, Saif Zaman, Boris Il'ich Chobrutskiy
Abstract: The present invention discloses a method for preventing the formation of calcified deposits or inside an isolated biological matrix comprising the step of contacting said isolated biological matrix with a solution comprising a mixture of phenolic compounds.
Abstract: Provided are methods, compositions and kits for depleting host nucleic acid in a biological sample, said sample having been previously obtained from an animal host.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
April 2, 2024
Assignee:
UEA Enterprises Limited
Inventors:
Justin Joseph O'Grady, Gemma Louise Kay, Themoula Charalampous, Alp Aydin, Riccardo Scotti
Abstract: The present application is directed to methods of performing chemical reactions, including multi-step chemical reactions in which two or more of the reagents in the chemical reaction are incorporated or entrapped in a solid polymeric structure comprising pullulan. In certain embodiments, the chemical reaction or multi-step reaction serves as a sensor. Accordingly the present application is also directed to sensors for performing the methods of the application. In certain embodiments, at least one of the reagents is a biomolecule and the sensor is a biosensor. In certain other embodiments, the solid polymeric structure comprising pullulan and the reagents for performing a chemical reaction form a convenient device for performing a chemical reaction.
Type:
Grant
Filed:
June 28, 2021
Date of Patent:
March 26, 2024
Assignee:
McMaster University
Inventors:
Carlos Filipe, John D. Brennan, Robert Pelton, Sana Jahanshahi-Anbuhi, Yingfu Li
Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.
Abstract: The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide.
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
March 12, 2024
Assignee:
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Inventors:
Athanasios Typas, Ana Rita Gontao Brochado, Stephan Göttig
Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
June 7, 2023
Date of Patent:
March 5, 2024
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: The present disclosure generally relates to a fish feed or fish feed product including a binding agent that increases the particle size and stability of feces produced by fish that consume the fish feed or fish feed product. In general, the fish feed will include a binding against such as locust bean gum, cassia gum, xanthan gum, tara gum, or combinations thereof. Also provided are methods for increases fish feces stability and methods for eliminating suspended solids from a recirculating aquaculture system.
Type:
Grant
Filed:
August 8, 2022
Date of Patent:
February 20, 2024
Assignee:
CAN TECHNOLOGIES, INC.
Inventors:
Dominic Andre Nanton, Peter Bjorn Rugroden, Kari Juhani Ruohonen, Marc Turano, Terje Utne
Abstract: Object of the present invention is to provide an intestinal immune-enhancing agent that can sufficiently increase IgA in the intestinal tract with a low dose while maintaining an increased amount of IgA for an extended period of time. Provided is an intestinal immune-enhancing agent containing a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1.
Abstract: A composition includes a sugar source and inositol. The sugar source is one more sugars select from the group consisting of glucose, sucrose, sucrolose, tagatose, galactose, high fructose corn syrup, fructose, isoglucose, and rhamnose. The composition of sugar and inositol has an unique properties that prevents or limits the signaling of TNF-? and associated pro-inflammatory cytokines when metabolized by an individual consuming the composition. Accordingly, the composition can be advantageously used to control blood glucose levels, treat diabetes and related conditions as well as treat diseases based on an inflammatory response.
Abstract: The disclosure provides for the use of an oligosaccharide for the treatment of liver disease. More particularly, the disclosure provide methods and composition for treating liver disease comprising administering 2?-FL to a subject.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
February 13, 2024
Assignee:
The Regents of the University of California
Abstract: The present disclosure relates to inhibited waxy starches and methods for using them. One aspect of the disclosure is an inhibited waxy starch based on maize, wheat, or tapioca having an amylopectin content in the range of 90-100%; and a sedimentation volume in the range of 10-50 mL/g; in which the amylopectin fraction of the inhibited waxy starch based on maize, wheat, or tapioca has no more than 48.5% medium-length branches having a chain length from 13-24 (measured by a valley-to-valley method as described herein), and the starch is not pregelatinized. Methods of using the starch materials in food products are also described.
Type:
Grant
Filed:
September 1, 2021
Date of Patent:
February 13, 2024
Assignee:
Tate & Lyle Solutions USA LLC
Inventors:
Judith K. Whaley, Weichang Liu, Yuqing Zhou, Xian Chen, Leslie George Howarth, Mark Beltz
Abstract: The present application relates to an orally administered pharmaceutical composition or kit for eradicating Helicobacter pylori, including a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition and kit of the present invention may further include a ?-lactam antibiotic and/or a gastric acid inhibitor.
Type:
Grant
Filed:
June 24, 2019
Date of Patent:
February 6, 2024
Assignee:
KOREA INSTITUTE OF GEOSCIENCE AND MINERAL RESOURCES
Inventors:
Jae-Hwan Kim, Il-Mo Kang, Young-Goo Song, Ki-Min Roh, Yun-Goo Song, Sung-Man Seo, Dae-Young Kim
Abstract: The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.